Notch信號(hào)通路進(jìn)化保守，分為經(jīng)典通路和非經(jīng)典通路。生理上，Notch受體經(jīng)3次切割后釋放胞內(nèi)結(jié)構(gòu)域NICD至細(xì)胞核中，調(diào)節(jié)靶基因的轉(zhuǎn)錄，對(duì)動(dòng)物發(fā)育、組織更新修復(fù)等生物過(guò)程進(jìn)行調(diào)控；病理上，Notch的遺傳突變或信號(hào)異?？纱龠M(jìn)或抑制多種疾病的進(jìn)展，在癌癥和非癌性疾病中存在著復(fù)雜機(jī)制。雖然在研藥物較多，涉及Notch信號(hào)通路的各個(gè)環(huán)節(jié)，但仍未有明確有效的上市藥物。因此對(duì)Notch途徑進(jìn)行更深入的研究，依照疾病類(lèi)型及Notch信號(hào)通路不同環(huán)節(jié)進(jìn)行整體評(píng)估和探討，進(jìn)而發(fā)現(xiàn)更有希望的靶向Notch的治療方法是非常必要的。

Notch signaling pathway evolved conservatively. The Notch signaling pathways include 'canonical' and 'non-canonical' pathways. Physiologically, the intracellular domain NICD is released into the nucleus after Notch receptor is cleaved three times, and then regulates biological processes such as animal development, tissue renewal and repairment by regulating the transcription of target genes in nucleus. Notch genetic mutations or signaling abnormalities can promote or inhibit the progression of various diseases and the mechanism is complex in cancer and non-cancer diseases. A series of drugs candidates involved in the Notch signaling pathway have been evaluated although there are no drugs on the market yet. Therefore, it is necessary to study the Notch pathway thoroughly.